Navigation Links
Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
Date:10/12/2008

SEATTLE, Oct. 13 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) has been selected to present at three upcoming investor conferences. The conferences include the 7th Annual BIO Investor Forum in San Francisco in October, the 19th Annual Oppenheimer & Co. Healthcare Conference, and the 9th Annual Acumen BioFin Rodman & Renshaw Healthcare Conference in November, both in New York City.

The presentations will be webcast live with slides, and available for replay after the presentation at http://www.celltherapeutics.com.

BIO Investor Forum

CTI Presentation: Thursday, October 30, 2008

8:00 AM PT/11:00 AM ET/4:00 PM CET

Room TBA, Palace Hotel, San Francisco

Oppenheimer & Co. Healthcare Conference

CTI Presentation: Monday, November 3, 2008

8:00 AM ET/2:00 PM CET/5:00 AM PT

Astor Room, Waldorf-Astoria Hotel, New York City

Acumen BioFin Rodman & Renshaw Healthcare Conference

CTI Presentation: Tuesday, November 11, 2008

10:45 AM EST/4:45 PM CET/7:45 AM PST

Kennedy I, New York Palace Hotel, New York City

Media Contact: Investors Contact:

Cell Therapeutics, Inc. Cell Therapeutics, Inc.

Dan Eramian Ed Bell

T: 206.272.4343 T: 206.272.4345

F: 206.272.4434 Lindsey Jesch Logan

E: media@ctiseattle.com T: 206.272.4347

http://www.celltherapeutics.com/press_room F: 206.272.4434

http://www.celltherapeutics.com/investors E: invest@ctiseattle.com


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
2. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
3. Cell Therapeutics, Inc. Announces Reverse Stock Split
4. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
5. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
6. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
7. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
8. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
9. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
10. Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt
11. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb. 23, 2017  Seattle,s upscale Capitol Hill neighborhood, with its ... place for a head lice treatment salon to set up ... Tuscan restaurant and a French bistro on E Madison Ave, ... aren,t just any old lice clinic, we pride ourselves on ... and release some of the stigma associated with lice. Everyone ...
(Date:2/23/2017)... INDIANAPOLIS, Ind. (PRWEB) , ... February 23, 2017 ... ... Commercialization Award during the 12th annual Inventors Recognition Reception at Purdue Research ... annually to a faculty member in recognition of outstanding contributions to, and success ...
(Date:2/23/2017)... DIEGO , Feb. 23, 2017 ... research tools, announced the acquisition of GenWay Biotech ... a comprehensive service and product offering for both ... acquisition will facilitate growth and enhance capabilities for ... antibodies, and ELISA assays will nicely complement ASB,s ...
(Date:2/22/2017)... ... February 22, 2017 , ... Kernel , a ... Systems, LLC (KRS) clinical development program. KRS is a neurotechnology spin-out from ... and clinical applications. The terms of the transaction were not disclosed. , ...
Breaking Biology Technology:
(Date:1/31/2017)... Jan. 31, 2017  Spero Therapeutics, LLC, a ... the treatment of bacterial infections, today announced it ... candidates from Pro Bono Bio Ltd (PBB) to ... multi-drug resistant forms of Gram-negative bacteria.   The assets ... Ltd, a PBB group company. "The ...
(Date:1/26/2017)... 2017  Acuity Market Intelligence today released the ... Identity".  Acuity characterizes 2017 as a "breakout" year ... reflects a new understanding of the potential benefits ... digital identity are often perceived as threats to ... Principal of Acuity Market intelligence. "However, taken together ...
(Date:1/24/2017)... 2017  It sounds simple and harmless—an electronic ... vital signs and alerts parents on their smart ... level drops. But pediatric experts argue that such ... no evidence of medical benefits, especially to healthy ... to parents of healthy babies, promising peace of ...
Breaking Biology News(10 mins):